Literature DB >> 12624112

A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase.

Jun Ninomiya-Tsuji1, Taisuke Kajino, Koichiro Ono, Toshihiko Ohtomo, Masahiko Matsumoto, Masashi Shiina, Masahiko Mihara, Masayuki Tsuchiya, Kunihiro Matsumoto.   

Abstract

TAK1, a member of the mitogen-activated kinase kinase kinase (MAPKKK) family, participates in proinflammatory cellular signaling pathways by activating JNK/p38 MAPKs and NF-kappaB. To identify drugs that prevent inflammation, we screened inhibitors of TAK1 catalytic activity. We identified a natural resorcylic lactone of fungal origin, 5Z-7-oxozeaenol, as a highly potent inhibitor of TAK1. This compound did not effectively inhibit the catalytic activities of the MEKK1 or ASK1 MAPKKKs, suggesting that 5Z-7-oxozeaenol is a selective inhibitor of TAK1. In cell culture, 5Z-7-oxozeaenol blocked interleukin-1-induced activation of TAK1, JNK/p38 MAPK, IkappaB kinases, and NF-kappaB, resulting in inhibition of cyclooxgenase-2 production. Furthermore, in vivo 5Z-7-oxozeaenol was able to inhibit picryl chloride-induced ear swelling. Thus, 5Z-7-oxozeaenol blocks proinflammatory signaling by selectively inhibiting TAK1 MAPKKK.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12624112     DOI: 10.1074/jbc.M207453200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  177 in total

1.  Autoactivation of transforming growth factor beta-activated kinase 1 is a sequential bimolecular process.

Authors:  Roland Scholz; Corinne L Sidler; Ramon F Thali; Nicolas Winssinger; Peter C F Cheung; Dietbert Neumann
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Total synthesis of LL-Z1640-2 utilizing a late-stage intramolecular Nozaki-Hiyama-Kishi reaction.

Authors:  Christopher A Leclair; Matthew B Boxer; Craig J Thomas; David J Maloney
Journal:  Tetrahedron Lett       Date:  2010-12-29       Impact factor: 2.415

3.  Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells.

Authors:  H Yang; Z Wang; J E Capó-Aponte; F Zhang; Z Pan; P S Reinach
Journal:  Exp Eye Res       Date:  2010-07-07       Impact factor: 3.467

4.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

5.  Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice.

Authors:  Ling Yang; Yoon Seok Roh; Jingyi Song; Bi Zhang; Cheng Liu; Rohit Loomba; Ekihiro Seki
Journal:  Hepatology       Date:  2013-12-18       Impact factor: 17.425

6.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

Review 7.  Ubiquitin signalling in the NF-kappaB pathway.

Authors:  Zhijian J Chen
Journal:  Nat Cell Biol       Date:  2005-08       Impact factor: 28.824

Review 8.  Targeting TLR4-dependent inflammation in post-hemorrhagic brain injury.

Authors:  Jason K Karimy; Benjamin C Reeves; Kristopher T Kahle
Journal:  Expert Opin Ther Targets       Date:  2020-04-17       Impact factor: 6.902

Review 9.  Molecular basis of NF-κB signaling.

Authors:  Johanna Napetschnig; Hao Wu
Journal:  Annu Rev Biophys       Date:  2013-03-11       Impact factor: 12.981

10.  Genes for the biosynthesis of the fungal polyketides hypothemycin from Hypomyces subiculosus and radicicol from Pochonia chlamydosporia.

Authors:  Christopher D Reeves; Zhihao Hu; Ralph Reid; James T Kealey
Journal:  Appl Environ Microbiol       Date:  2008-06-20       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.